NEUPOGEN

(Neupogen)

ApprovedSmall molecule

Amgen

NEUPOGEN is one of 107 small molecule programs targeting Neutropenia. It is currently in Approved.

Indications

Total Trials

Active Trials

106

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

IschemiaActive, not recruiting

LymphomaActive, not recruiting

Premature Ovarian InsufficiencyActive, not recruiting

NeutropeniaApproved

Active, not recruiting

IschemiaApproved

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Premature Ovarian InsufficiencyPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

NEUPOGEN

Amgen

Approved

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

PEG-Intron

Merck & Co.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

3 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Not yet recruiting

Efficacy and Safety

NCT06504901

Clinical

Trials by Indication[1]

Neutropenia2 trials

Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia

Completed·OOttawa Hospital Research Institute·Phase 4·NCT02816112·458 enrolled

A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia

Completed·OOttawa Hospital Research Institute·Phase 4·NCT02816164·324 enrolled

Premature ovarian insufficiency1 trial

The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency

Completed·TTrio Fertility·Phase 2·NCT06117982·11 enrolled

Carboplatin1 trial

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00074165·17 enrolled

Stem Cell Transplant1 trial

Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

Terminated·—·Phase 3·NCT02489500·3 enrolled

Adult1 trial

Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostim® Compared to Neupogen® in Healthy Adult Volunteers

Completed·DDong-A ST Co., Ltd.·Phase 1·NCT02725086·56 enrolled

9 more indications

Efficacy and Safety1 trial

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University··NCT06504901·30 enrolled

Granulocyte Colony Stimulating Factor1 trial

Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)

Completed·SShantha Biotechnics Limited·Phase 3·NCT00776165·126 enrolled

Lymphoma1 trial

Tandem Auto-Allo Transplant for Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01181271·42 enrolled

Radiotherapy1 trial

A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy

Withdrawn·—·Phase 1·NCT03612466

Safety and Efficacy1 trial

Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs)

Completed·TTarix Pharmaceuticals·Phase 1·NCT01543971·18 enrolled

Recurrent1 trial

Use of Gcsf in Patients With Recurrent Ivf/Icsi Failure

Completed·—·N/A·NCT03023774·20 enrolled

Ischemia1 trial

Use Art-assist and Neupogen to Treat Chronic Limb Ischemia

Withdrawn·UUniversity of Chicago·Phase 4·NCT02408991

Clinical Trial1 trial

Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®

Completed·BBiocad·Phase 1·NCT02762799·60 enrolled

Hyperbaric Oxygen Therapy1 trial

Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers

Withdrawn·UUniversity of Maryland, Baltimore·Phase 2·NCT02682953

Regulatory

FDA Approval Timeline[4]

Feb 20, 1991

NEUPOGEN

BLA BLA103353

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Neupogen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neupogen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neupogen. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA103353). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Amgen

NEUPOGEN

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Neutropenia2 trials

Premature ovarian insufficiency1 trial

Carboplatin1 trial

Stem Cell Transplant1 trial

Adult1 trial

Efficacy and Safety1 trial

Granulocyte Colony Stimulating Factor1 trial

Lymphoma1 trial

Radiotherapy1 trial

Safety and Efficacy1 trial

Recurrent1 trial

Ischemia1 trial

Clinical Trial1 trial

Hyperbaric Oxygen Therapy1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News